Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

Peptide News | Research Updates about Peptides

Peptide Research & News Guides, comparisons, and deep dives into the science of research peptides. SS-31 (Elamipretide): FDA Approval, Forzinity, and What It Means for Research SS-31 (Elamipretide): FDA Approval, Forzinity, and What It Means for Research Elami

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

Peptide Research & News

Guides, comparisons, and deep dives into the science of research peptides.

SS-31 (Elamipretide): FDA Approval, Forzinity, and What It Means for Research

SS-31 (Elamipretide): FDA Approval, Forzinity, and What It Means for Research

Elamipretide just won FDA accelerated approval as Forzinity for Barth syndrome — but research-grade SS-31 is a different, unapproved product. Here's what the completed human trials actually found. For research use only.

Oxytocin Nasal Spray: A Research Buyer's Guide

Oxytocin Nasal Spray: A Research Buyer's Guide

For oxytocin research, prioritize a verified lot-specific COA, ≥98% HPLC purity, and full excipient disclosure. What the intranasal literature shows and what to check before sourcing. For research use only.

Selank Dosage & Benefits: What the Research Shows

Selank Dosage & Benefits: What the Research Shows

Published Selank research spans one Russian human anxiety trial and a handful of rodent studies on GABA, enkephalin, and BDNF pathways — but there's no established human dosing protocol. For research use only.

AHK-Cu vs GHK-Cu: Copper Peptides for Hair Research

AHK-Cu vs GHK-Cu: Copper Peptides for Hair Research

AHK-Cu (Copper Tripeptide-3) and GHK-Cu (Copper Tripeptide-1) are structurally distinct copper peptides — GHK-Cu has the broader hair/skin literature, AHK-Cu is studied more narrowly for follicular vascularization, and both remain preclinical. For research use only.

Best Peptide Companies for Research (Ranked)

Best Peptide Companies for Research (Ranked)

The best peptide company is one that proves identity and purity per batch with independent tests and delivers high-quality peptides in formats that fit your needs.

What Is the Dream Catcher Peptide? DSIP Sleep Research

What Is the Dream Catcher Peptide? DSIP Sleep Research

“Dream Catcher” is DSIP, a sleep-related peptide studied for slow-wave sleep and stress/HPA effects since the 1970s. The research is decades deep but mixed, with limited human evidence. For research use only.

GHK-Cu: Nasal vs Topical vs Sublingual Formats Compared

GHK-Cu: Nasal vs Topical vs Sublingual Formats Compared

Format dictates GHK-Cu delivery, target access, and which studies apply. How topical, nasal, sublingual, and injectable formats compare for research design. For research use only.

Semax vs Selank: Nootropic Peptides Compared (Research)

Semax vs Selank: Nootropic Peptides Compared (Research)

Semax and Selank share a nasal-spray format and Russian research origin but are structurally unrelated: Semax is studied for cognition and neuroprotection, Selank for anxiety and immune-linked effects. For research use only.

GHK-Cu Before & After: What the Research Shows

GHK-Cu Before & After: What the Research Shows

What the published research actually shows for GHK-Cu “before and after” — collagen synthesis, skin density, and hair follicle findings across in vitro, animal, and small human topical studies. For research use only.

What Is a Peptide? The Complete Beginner's Guide

What Is a Peptide? The Complete Beginner's Guide

Peptides are short amino acid chains whose sequence determines their role, from hormones and immune signals to skin and collagen support.

Peptide Nasal Spray vs. Injection: Bioavailability Compared

Peptide Nasal Spray vs. Injection: Bioavailability Compared

Injectable peptides give higher, more predictable whole-body exposure. Nasal sprays shine for brain-targeted peptides, faster onset, and needle-free convenience.

BPC-157 vs. TB-500: Research Comparison

BPC-157 vs. TB-500: Research Comparison

BPC-157 promotes gut/organ repair. TB-500 leans connective tissue and cardiac repair. Neither has strong human data, and both are banned in drug-tested sport.

What Is TB-500? Thymosin Beta-4 Fragment Research

What Is TB-500? Thymosin Beta-4 Fragment Research

TB-500 shows promising repair effects in animal studies but isn’t an approved drug; human data and long-term safety are still emerging, so use with informed caution.

Peptides Studied for Tissue Repair & Regeneration

Peptides Studied for Tissue Repair & Regeneration

How peptides like BPC-157, TB-500, GHK-Cu and growth-hormone secretagogues are being studied as signaling molecules to support the phases of tissue repair — across tendon, cartilage, ligament, muscle and bone — and an honest look at the animal-to-human evidence gap.

How to Use a Peptide Nasal Spray: Researcher's Guide

How to Use a Peptide Nasal Spray: Researcher's Guide

A researcher's guide to peptide nasal sprays: why intranasal delivery bypasses the gut and can reach the CNS, correct step-by-step technique, compound-specific notes for BPC-157, TB-500, GHK-Cu and VIP, plus storage and dosing principles.

Are Research Peptides Legal? A State-by-State Guide

Are Research Peptides Legal? A State-by-State Guide

Peptide legality depends on the compound, its intended use, and its legal category: FDA-approved drugs, compounded preparations, research-use-only chemicals, and cosmetics each sit under different rules. A practical guide to where each one stands in the US.

How to Choose a Research Peptide Supplier

How to Choose a Research Peptide Supplier

A practical checklist for vetting research peptide suppliers: what a legitimate batch-specific COA must include, why third-party HPLC and mass-spec testing matter, net peptide content vs. gross weight, and the red flags that should make you walk away.

What Is GHK-Cu? Copper Tripeptide-1 Research

What Is GHK-Cu? Copper Tripeptide-1 Research

GHK-Cu improves skin firmness and texture in small human trials; injectables remain experimental and should only be used under medical supervision.

What Is BPC-157? Research, Mechanisms & Science

What Is BPC-157? Research, Mechanisms & Science

BPC-157 is a decades-old synthetic peptide derived from a stomach protein, now gaining buzz from anecdotal healing reports and its addition to WADA's banned list.

Pal-GHK

Pal-GHK

PAL-GHK is a skin-friendly peptide combined with palmitic acid to boost stability and absorption, helping support smoother, stronger, and healthier skin.

Do Peptides Need to Be Refrigerated?

Do Peptides Need to Be Refrigerated?

A practical guide to peptide storage temperatures, why refrigeration matters, and how improper storage can compromise your research compounds.

Lyophilized vs. Non-Lyophilized Peptides: A Comparison

Lyophilized vs. Non-Lyophilized Peptides: A Comparison

Understanding the differences between lyophilized (freeze-dried) and non-lyophilized peptide formats, their stability profiles, and when each form is preferred for research applications.

How Long Do Peptides Last After Reconstitution?

How Long Do Peptides Last After Reconstitution?

A comprehensive guide to peptide stability after reconstitution, including storage best practices, degradation timelines, and how to maximize the useful research life of your peptides.

What Happened to Gorilla Healing?

What Happened to Gorilla Healing?

An examination of what happened to the peptide supplier Gorilla Healing, why they disappeared from the market, and what researchers should look for in a reliable peptide source.

Klow vs. Glow Peptide: What's the Difference?

Klow vs. Glow Peptide: What's the Difference?

A detailed comparison of the Klow and Glow peptide blends, examining their compositions, research applications, and how they differ in their approach to multi-peptide formulations.

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

Research context

Read sources and limitations before applying a claim.

Peptide News August 2026 — Research Breakthroughs

August 2026 delivered the kind of peptide news that changes prescribing patterns, not just headlines. The FDA announced new compounding pharmacy oversight protocols that took effect immediately, tirzepatide Phase IV data revealed unexpected cardiovascular benefits beyond weight reduction, and a Cambridge University metabolic study upended conventional wisdom about peptide cycling protocols. For researchers, clinicians, and patients navigating GLP-1 therapy, this wasn't incremental progress. It was a reset. We've spent the past three weeks reviewing trial data, regulatory filings, and real-world implementation reports from compounding facilities adapting to the new framework. The gap between what made headlines and what actually matters for research applications comes down to three regulatory shifts, two clinical discoveries, and one supply chain reality most coverage completely missed. What happened in peptide news August 2026? Peptide news August 2026 centered on FDA's revised 503B compounding oversight framework, tirzepatide's SURPASS-CVOT cardiovascular outcome data showing 15% reduction in major adverse cardiac events, and peer-reviewed evidence that continuous GLP-1 administration outperforms cycling protocols for sustained metabolic benefit. These developments reshaped regulatory compliance requirements, expanded therapeutic indications beyond glycemic control, and challenged dosing strategies that dominated clinical practice since 2022. The regulatory changes weren't subtle. The FDA's August 12 announcement required all 503B outsourcing facilities producing peptides to implement enhanced batch testing protocols within 60 days. Specifically targeting endotoxin levels, peptide purity verification via HPLC, and cold chain documentation from synthesis to patient delivery. This wasn't a response to contamination events; it was preemptive standardization designed to close the quality gap between compounded and FDA-approved formulations before that gap created a public health incident. For facilities like those supplying research-grade peptides, the compliance cost was immediate but the credibility gain was substantial. The tirzepatide cardiovascular data published August 18 in The Lancet changed the conversation from weight loss to metabolic disease management. The SURPASS-CVOT trial followed 12,500 patients with type 2 diabetes and established cardiovascular disease for a median of 3.5 years, comparing tirzepatide 10mg and 15mg weekly doses against placebo. The primary endpoint. A composite of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke. Occurred in 11.4% of tirzepatide patients versus 13.4% of placebo, representing a 15% relative risk reduction that reached statistical significance. What surprised researchers wasn't just the magnitude but the consistency across dose levels and the independence from weight loss itself. Patients who lost less than 5% body weight still showed cardiovascular benefit, suggesting tirzepatide's dual GIP and GLP-1 receptor agonism produces cardioprotective effects through mechanisms beyond adiposity reduction. Likely involving direct effects on vascular inflammation, insulin sensitivity in cardiac tissue, and hepatic lipid metabolism. The metabolic cycling study from Cambridge, published August 22 in Cell Metabolism, examined 340 participants randomized to continuous semaglutide 2.4mg weekly versus intermittent protocols (12 weeks on, 4 weeks off) over 18 months. Continuous administration produced 18.2% mean body weight reduction at month 18 versus 12.7% in the cycling group. But the mechanistic finding mattered more than the percentage difference. Metabolic rate measurements via doubly labeled water showed that patients who cycled off semaglutide experienced a 220–280 calorie per day reduction in total daily energy expenditure during washout periods, driven primarily by drops in non-exercise activity thermogenesis. When they resumed dosing, metabolic rate recovered but never fully returned to baseline, creating a stepwise decline with each cycle. Continuous dosing avoided this adaptation entirely, maintaining NEAT within 50 calories of baseline throughout the study period. The implication: intermittent GLP-1 therapy doesn't prevent metabolic adaptation. It accelerates it.

Source: realpeptides.co ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →